Prime-boost Ebola vaccine yields immune response at one year - Africa Health
A prime-boost Ebola vaccine regimen that is well into clinical trials shows immune response one year after vaccination, the longest so far for experimental vaccines against the disease using that strategy, researchers reported yesterday (14 March). The trial involved two vaccine candidates, a priming dose of the adenovirus vectored Ad26.ZEBOV developed by Johnson & Johnson andRead More